HKPD stock forecast, quote, news & analysis
Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong... Show more
Why Cellyan Biotechnology (HKPD) Stock Is Down -16% in the Last 30 Days
Key Takeaways
- Cellyan Biotechnology (HKPD) fell roughly 16% over the last 30 days on a split-adjusted basis, extending a multi-month downtrend for the Hong Kong-based OTC pharmaceutical services provider.
- A 1-for-20 reverse stock split took effect October 26, 2026, intended to restore compliance with Nasdaq's $1.00 minimum bid price requirement.
- Fundamental pressure persists: fiscal 2026 revenue declined about 34% year over year, and the company reported a net loss.
- Nasdaq granted a second 180-day compliance period running through January 11, 2027, which keeps the listing in place for now but does not guarantee continued compliance.
- Post-split trading has remained volatile, with the shares sliding further into the final sessions of October.
- For deeper data on this ticker, explore Price Targets, Earnings, and Forecast pages for HKPD.
- Discover AI-driven trading strategies for HKPD and other names on the Trending AI Robots page.
Cellyan Biotechnology (HKPD) Company Overview and Market Position
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD), formerly Hong Kong Pharma Digital Technology Holdings Limited, is a Hong Kong-based provider of over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain services. The company operates through two primary subsidiaries: Joint Cross Border Logistics Company Limited, which handles OTC pharmaceutical cross-border supply chain services, and V-Alliance Technology Supplies Limited, which focuses on cross-border procurement and distribution.
The business connects overseas OTC drug suppliers, logistics providers, and Chinese e-commerce merchants to deliver regulated pharmaceutical products to customers in Mainland China. Its services span pre-consultation, product review, regulatory enlistment with Hong Kong's Department of Health, permit acquisition, warehousing, packaging, and end-to-end delivery. Investors follow the stock for its niche exposure to cross-border health-product demand in Greater China, though the micro-cap name carries elevated liquidity, compliance, and fundamental risks.
Cellyan Biotechnology (HKPD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HKPD declined approximately 16% on a split-adjusted basis, moving from about $2.32 in late September to roughly $1.95 at the end of October. The decline was punctuated by a sharp single-session drop of about 11% in the final October trading session.
The broader quarterly trend is considerably steeper. From approximately $7.28 in late August to $1.95 at the end of October, the shares fell roughly 73% on a split-adjusted basis, reflecting sustained selling pressure that predates the recent reverse stock split. The stock's trajectory has been downward throughout the period, with brief consolidations followed by renewed declines.
What Drove HKPD Stock Price in the Last 30 Days
The dominant catalyst over the past month was the company's announcement and implementation of a 1-for-20 reverse stock split, effective October 26, 2026. Cellyan stated the consolidation is primarily intended to help it regain compliance with Nasdaq's $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
The reverse split is a corporate-action adjustment rather than an improvement in business fundamentals: it reduces the share count and mechanically raises the per-share price without changing shareholders' percentage ownership or the company's market capitalization. Following the split, the shares resumed a downward drift, and the stock recorded a notable single-day decline in late October. Broader sentiment remains pressured by the company's weak financial results, including a roughly 34% year-over-year revenue decline and a net loss for the fiscal year ended March 31, 2026.
What Drove HKPD Stock Performance Over the Last Quarter
Over the past quarter, HKPD's decline has been shaped by a combination of compliance concerns and deteriorating fundamentals. Nasdaq first issued a bid-price deficiency notice in January 2026, and the company received a second 180-day grace period in July 2026 that runs through January 11, 2027. The lingering threat of delisting has weighed on investor confidence for months.
At the same time, the company's financials deteriorated. Revenue for fiscal 2026 fell about 34% to approximately $13.4 million, gross margin compressed, and the company swung to a net loss of about $1.1 million. The independent auditor included a material uncertainty related to going concern in its report, citing the net loss, net cash outflows from operations, and the revenue decline. These factors have combined to keep sustained selling pressure on the stock throughout the quarter.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are currently demonstrating strong performance. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are surfaced in this section. The bots vary in strategy, timeframe, and performance metrics, ranging from short-term swing trading approaches to longer-horizon trend strategies. For investors and traders seeking a systematic, data-driven perspective on market activity, the page provides a way to explore automated strategies that can complement manual analysis.
HKPD Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several factors in the months ahead. First is Nasdaq compliance: the company must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days before the January 11, 2027 deadline to avoid delisting risk. Second, the company's delayed annual filing (Form 20-F) and any subsequent earnings releases will clarify whether revenue and margins have stabilized.
Additional items to watch include the company's customer concentration, its reliance on cross-border e-commerce demand in Greater China, competitive pressures in OTC pharmaceutical distribution, and the broader regulatory environment affecting cross-border trade. Given the going-concern disclosure and micro-cap liquidity, the stock may remain susceptible to elevated volatility. This analysis does not constitute investment advice or a prediction of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HKPD in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
HKPD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 14 of 15 cases where HKPD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HKPD's RSI Oscillator exited the oversold zone, 10 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where HKPD advanced for three days, in 57 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HKPD as a result. In 27 of 27 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HKPD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for HKPD entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.566) is normal, around the industry mean (14.423). P/E Ratio (6.136) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.147) is also within normal values, averaging (4.260).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. HKPD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HKPD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalDistributors